917
Participants
Start Date
October 28, 2010
Primary Completion Date
February 1, 2012
Study Completion Date
February 28, 2012
1mg Finasteride active
1mg finasteride active, by mouth once daily
0.02mg dutasteride
0.02mg dutasteride active, by mouth once daily
0.1mg dutasteride
0.1mg dutasteride active, by mouth once daily
0.5mg dutasteride
0.5mg dutasteride active, by mouth once daily
Finasteride placebo
finasteride placebo, by mouth once daily
Dutasteride placebo
dutasteride placebo, by mouth once daily
GSK Investigational Site, Taipei
GSK Investigational Site, Taipei
GSK Investigational Site, Manila
GSK Investigational Site, Quezon City
GSK Investigational Site, Makati City
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Tanauan City, Batangas
GSK Investigational Site, Patumwan Bangkok
GSK Investigational Site, Rajthevee Bangkok
GSK Investigational Site, Bangkoknoi Bangkok
GSK Investigational Site, Naucalpan
GSK Investigational Site, Zapopan, Jalisco
GSK Investigational Site, Chiang Mai
GSK Investigational Site, Monterrey
GSK Investigational Site, Tainan City
GSK Investigational Site, Mazatlan, Sinaloa
GSK Investigational Site, Moscow
GSK Investigational Site, St'Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Ryazan
GSK Investigational Site, Nizhny Novgorod
GSK Investigational Site, Santiago
GSK Investigational Site, CABA
GSK Investigational Site, Ciudad Autonoma de Buenos Aires
GSK Investigational Site, La Boca
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Viña del Mar
GSK Investigational Site, Fukuoka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Mexico City
GSK Investigational Site, Mexico City
GSK Investigational Site, Lima
GSK Investigational Site, Lima
GSK Investigational Site, Lima Cercado
GSK Investigational Site, Quezon City
GSK Investigational Site, Taipei
Lead Sponsor
GlaxoSmithKline
INDUSTRY